Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer extends license for Entelos research software

Pfizer extends license for Entelos research software

28th June 2010

Pfizer has agreed a new deal with Entelos that will allow it to gain wider access to the life sciences company’s Metabolism PhysioLab research software platform.

The two companies have signed a non-exclusive perpetual license agreement, allowing Pfizer to access PhysioLab Modeler software and the PhysioLab Simulation Server in its research into diabetes and obesity.

This software allows Pfizer to create “virtual patients” using a range of behavioural and biological data, thereby leading to a greater understanding of the diseases that can underpin the development of new treatments.

Julie Thomas Goggin, Entelos’ chief executive officer, said the company was looking forward to continuing its relationship with its “ardent supporter” Pfizer.

She added: “We are thrilled that our highly predictive, established Metabolism PhysioLab platform will be available to Pfizer on a perpetual basis to help accelerate its compound development.”

Last week, Pfizer published new data from a clinical trial of the heart disease treatment Caduet, illustrating its long-term health benefits.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.